Ilmago (Tamsulosin Hydrochloride, Dutasteride)

Ilmago, containing tamsulosin and dutasteride, is used in the management of benign prostatic hyperplasia, a condition characterized by prostate enlargement.

• Benign prostatic hyperplasia: reduces prostate volume and improves urinary flow.
• Lower urinary tract symptoms due to BPH: alleviates urgency, frequency and nocturia.
• Risk of acute urinary retention: decreases the likelihood of sudden inability to urinate.

• Ilmago combines two mechanisms: tamsulosin selectively antagonizes alpha‑1A adrenergic receptors in the prostate and bladder neck, relaxing smooth‑muscle tone and facilitating urine passage; dutasteride inhibits both type 1 and type 2 5‑alpha‑reductase enzymes, blocking conversion of testosterone to dihydrotestosterone, which leads to gradual reduction of prostate gland size. The dual action addresses both dynamic and static components of BPH.

Ilmago may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Dizziness or light‑headedness.
• Headache.
• Abnormal ejaculation or decreased libido.
• Nasal congestion or runny nose.
• Orthostatic hypotension.

Serious or Rare Side Effects

• Priapism (prolonged erection).
• Severe allergic reaction including rash, swelling or anaphylaxis.
• Intraoperative floppy iris syndrome during cataract surgery.
• Hepatic dysfunction or jaundice.

When prescribing Ilmago, clinicians should observe several precautionary measures to ensure patient safety.

• Monitor blood pressure: watch for orthostatic hypotension, especially after initiating therapy.
• Assess liver function: dutasteride is metabolized hepatically and may require periodic testing.
• Avoid use in patients with known hypersensitivity to either component.
• Caution in men scheduled for cataract surgery: risk of intraoperative floppy iris syndrome.
• Review concomitant medications that affect blood pressure or CYP3A4 metabolism.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Ilmago can interact with other medicines; understanding the level of interaction helps guide clinical decisions.

Major Interactions (Avoid)

• Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise dutasteride concentrations.
• Co‑administration with other alpha‑blockers (e.g., doxazosin, prazosin): increases risk of severe hypotension.
• Warfarin: may enhance anticoagulant effect and bleeding risk.

Moderate Interactions (Monitor Closely)

• Diuretics: additive blood‑pressure lowering effect; monitor for dizziness.
• Other antihypertensives: dose adjustments may be needed to avoid excessive hypotension.
• Phenytoin or carbamazepine: may reduce dutasteride plasma levels, potentially diminishing efficacy.